Showing results (501-510 of 535) with videos related to

Sort By:
Pageof 54
Cell|November 5, 2025
Disparate leukemia mutations converge on nuclear phase-separated condensatesGandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.
Cancer|April 1, 2021
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemiaCaitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, et al.
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
American Journal of Hematology|September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatmentCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology|October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLMusa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
Pageof 54